ÂÜÀòÂÒÂ×

Amine MAROUF has a diverse range of work experience in the field of healthcare and innovation. Amine started their career in 2016 as a Business Analyst at AstraZeneca, where they focused on oncology. In 2017, they joined BearingPoint as a Consultant, specializing in life sciences, and worked there until May 2017.

Later in 2017, Amine MAROUF took on the role of Principal at Kurma Partners, where they were responsible for market watch, deal opportunities sourcing, and selection in the healthcare sector. Amine also managed relationships with research centers, incubators, hospitals, and startup studios in Europe. Additionally, Amine served as an investment committee member, jury member, and speaker for various national innovation programs and events. Amine continues to hold this position.

In the same year, Amine MAROUF also became a Life Sciences investor at Paris Saclay Seed Fund. This role allowed him to further explore investment opportunities in the field.

Following their experiences at Kurma Partners and Paris Saclay Seed Fund, Amine MAROUF became involved with several companies in leadership and investment roles. Amine currently serves as a Board Member and Lead Investor at NaoX Technologies, Mila, and Lucine, and as a Board Observer and Co-Investor at FeetMe. These positions demonstrate their expertise in identifying and supporting innovative ventures.

In addition to their work with these companies, Amine MAROUF has also served as an Expert and Jury Member at Bpifrance since January 2018. This role involves assessing and evaluating projects in the innovation sector.

Prior to their extensive involvement in the healthcare and innovation fields, Amine MAROUF worked as an Entrepreneur and Innovation Consultant at Le Belvedere from June 2015 onwards.

Overall, Amine MAROUF's work experience showcases their strong background and expertise in healthcare, innovation strategy, investment, and business analysis.

Amine MAROUF has a diverse education history. Amine started their educational journey at Lycée Rabelais, although the specific time frame is not provided. Later, they pursued a two-year degree in biomedical sciences from Université Paris Cité, which they completed between 2004 and 2006. Amine then continued their studies at Université Paris Cité, where they obtained a Master's in Research in Health & Applied Sciences from 2007 to 2009. Concurrently, they also pursued a Magistère Européen de Génétique degree in Genetics from the same university, which they completed from 2006 to 2009. Finally, Amine attended ESSEC Business School from 2009 to 2011, where they earned a Master of Science degree in Management. It is unknown whether they have obtained any additional certifications, as the information about the certification they obtained from Autorité des marchés financiers (AMF) in France does not include the month and year of completion.